Table 2: The effect of Anti-CD3/CD28 induced the increases of inflammation-related cytokines in the PBMCs of RA and healthy control group.

RANKL 
(pmol/L)
OPG 
(pmol/L)
RANKL/OPGTNF-α
(pg/mL)
IL-17 
(pg/mL)
IL-6 
(pg/mL)
IL-4 
(pg/mL)

RA patient
 Vehicle control85.39 ± 5.540.53 ± 0.13171.10 ± 49.1112.55 ± 5.3246.23 ± 13.032884.35 ± 1389.034.53 ± 1.37
 Anti-CD3/CD28100.72 ± 11.980.57 ± 0.15190.24 ± 51.25508.52 ± 90.94606.76 ± 49.797939.02 ± 2108.859.46 ± 4.15
Healthy control
 Vehicle control67.22 ± 11.140.61 ± 0.18127.18 ± 14.076.68 ± 0.5525.48 ± 3.78152.87 ± 304.385.02 ± 2.53
 Anti-CD3/CD2883.09 ± 12.170.61 ± 0.07136.23 ± 13.42195.95 ± 52.83249.87 ± 17.632607.90 ± 232.989.77 ± 4.43

Values are expressed as mean ± standard deviation.